I’m guessing that news about possible Alzheimer’s disease treatments is still relevant to most of us, so I’ll start with that. The results of the lecanemab trial are published. The reaction is mixed. In the October “Odd & Ends” piece, I discussed in considerable detail the clinical trial of lecanemab in advance of publication of […]